A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
-
University of California Irvine, Orange, California, United States, 92868
Stanford University, Palo Alto, California, United States, 94304
University of Colorado, Denver, Colorado, United States, 80045
University of Florida, Gainesville, Florida, United States, 32608
University of Iowa, Iowa City, Iowa, United States, 52242
Kansas University Medical Center, Kansas City, Kansas, United States, 66205
Kennedy Krieger Institute, Baltimore, Maryland, United States, 21205
University of Massachusetts, Worcester, Massachusetts, United States, 01655
University of Rochester Medical Center, Rochester, New York, United States, 14642
Duke University, Durham, North Carolina, United States, 27708
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
16 Years to 70 Years
ALL
No
Avidity Biosciences, Inc.,
2028-07